Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: The Biomarker Utility in Risk Stratification in an Ambulatory Heart Failure: ST2 or Galectin-3?, Journal of Cardiology and Therapy, January 2016, ACT Publishing Group,
DOI: 10.17554/j.issn.2309-6861.2015.03.105.
You can read the full text:

Read

Contributors

The following have contributed to this page